{
    "root": "30535278-6d30-76bd-e063-6294a90a7534",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20250314",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        }
    ],
    "indications": "Pregabalin capsule is indicated for:\n                  \n                  \n                     \n                        Management of neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                     \n                        Management of postherpetic neuralgia\n                     \n                     \n                        Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older\n                     \n                     \n                         Management of fibromyalgia\n                     \n                     \n                        Management of neuropathic pain associated with spinal cord injury\n                     \n                  \n                  \n                     Pediatric use information is approved for Pfizer's LYRICA (pregabalin) Capsules and Oral  Solution products. However, due to Pfizer's marketing exclusivity rights, this drug product  is not labeled with that pediatric information.",
    "contraindications": "For adult indications, begin dosing at 150 mg/day. (2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain (2.2) 3 divided doses per day 300 mg/day within 1 week PHN (2.3) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day Adjunctive Therapy for Partial-Onset Seizures in Adult Patients 17 Years of Age and Older (2.4) 2 or 3 divided doses per day Maximum dose of 600 mg/day Fibromyalgia (2.5) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day Neuropathic Pain Associated with Spinal Cord Injury (2.6) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day • Dose should be adjusted in adult patients with reduced renal function. (2.7)",
    "warningsAndPrecautions": "75 mg capsules\n                  White to off White color granular powder filled in Size \"4\" hard gelatin capsules with White Opaque body imprinted \"PGBN\" and light blue Opaque cap imprinted \"75\" with black ink available in:\n                  NDC: 70518-2525-00\n                  NDC: 70518-2525-01\n                  NDC: 70518-2525-02\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Storage and Handling\n                  Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy \n       \n \n  \n                        [see Warnings and Precautions (5.2)]."
}